Case Type: Mergers & Acquisitions

GMS Inc. (NYSE: GMS) related to its sale to SRS Distribution for $110.00 per share without interest to GMS shareholders.

Couchbase, Inc. (NASDAQ: BASE) related to its sale to Haveli Investments for $24.50 per share in cash without interest to Couchbase shareholders.

SpartanNash Company (NASDAQ: SPTN) related to its sale to C&S Wholesale Grocers for $26.90 per share in cash without interest to SpartanNash shareholders.

Enzo Biochem, Inc. (OTCMKTS: ENZB) related to its sale to Battery Ventures for $0.70 per share in cash without interest to Enzo shareholders.

DNOW Inc. (NYSE: DNOW) related to its merger with MRC Global Inc. Upon completion of the proposed transaction, current DNOW shareholders will own approximately 56.5% of the combined company on a fully diluted basis.

Sage Therapeutics, Inc. (NASDAQ: SAGE) related to its sale to Supernus Pharmaceuticals, Inc. Upon completion of the proposed transaction, current Sage shareholders will receive $8.50 per share in cash, plus one non-tradable contingent value right collectively worth up to $3.50 per share in cash payable (i) $0.50 the first commercial sale of the drug Zurzuvae … Read more

Turnstone Biologics Corp. (NASDAQ: TSBX) related to its sale to XOMA Royalty Corporation in which existing Turnstone shareholders will receive $0.34 in cash per share and one non-transferable contingent value right.

Guaranty Bancshares, Inc. (NYSE: GNTY) related to its sale to Glacier Bancorp, Inc. Upon completion of the proposed transaction, existing Guaranty shareholders will receive 1.0000 share of Glacier common stock for each share of Guaranty (subject to certain adjustments).

Carisma Therapeutics Inc. (NASDAQ: CARM) related to its to OrthoCellix, Inc. Upon completion of the proposed transaction, existing Carisma shareholders are expected to own approximately 10% of the combined company.

Verve Therapeutics, Inc. (NASDAQ: VERV) related to its sale to Eli Lilly. Under the terms of the proposed transaction, Verve shareholders will receive $10.50 per share in cash, plus one non-tradeable contingent value right per share entitling the holder to receive up to an additional $3.00 per share upon the achievement of certain milestones.